Auburn University
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Clinical assessments will include phlebotomy (completed at weeks 0 and 8) and questionnaires which will be completed at weeks 0, 4, and 8 to assess changes in mood disorder symptomology and serum BDNF. 3 days of 24-hour diet recalls will be collected at weeks 0, 4 and 8. Daily reminders via Emitrr will be sent daily to ensure adherence to supplementation. This is an 8-week randomized placebo controlled trial looking at mood disturbance and serum BDNF in moderately depressed adults aged 18-50. Participants will be randomized into the intervention group or placebo with the intervention group co…
Inclusion Criteria: * Adults age 18-50 * Depression subscale score of \>9/21 on the DASS-21 * No change in medications or supplements over the past 3 months * Can read and speak English Exclusion Criteria: * Currently consume curcumin or green tea daily * Currently, pregnant, nursing, or trying to become pregnant * Currently diagnosed with a perimenopausal disorder
1,330 mg curcumin
350 mg Epigallocatechin gallate (EGCG)
Placebo to be consumed after randomization.
Arctuva estimate
Verify or correct the compensation shown for this listing.